Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

The pharmaceutical contract research and manufacturing (CRAM) market will register a CAGR of more than 9% by 2023
By: PR Newswire Association LLC. - 25 Apr 2019Back to overview list

NEW YORK, April 24, 2019 /PRNewswire/ -- About this market
The significant advances in their healthcare infrastructure and technological advances in their drug development processes. As a result, large and medium-sized pharmaceutical companies from developed countries are outsourcing the research and manufacturing operations of various drugs and therapies to the vendors in such countries. Factors such as the increasing number of US FDA-approved manufacturing plants in such countries also encourage outsourcing. The rapidly evolving market environment and the strong support of the Government of China help the country specialize in the research of drugs, including regenerative medicines and small-molecule based drugs. Therefore, the global pharmaceutical CRAM market is expected to grow strongly during the forecast period. Analysts have predicted that the pharmaceutical contract research and manufacturing (CRAM) market will register a CAGR of more than 9% by 2023.

Download the full report: https://www.reportbuyer.com/product/5770979/?utm_source=PRN

Market Overview
Growing need to focus on core competencies
One of the growing changes in the global pharmaceutical market is the increasing volume of outsourcing of partial or complete research and manufacturing processes to CROs and CMOs. This is primarily due to the rising focus of the sourcing companies on developing therapies for large indications such as oncology, neurology, and autoimmune disorders.
Stereotypical nature of CMOs
Despite the growing popularity of CMOs in emerging countries such as China and India, the global pharmaceutical CRAM market faces a major challenge from the limited offerings of the CMOs. This is currently a major challenge faced by CMOs, which is expected to significantly hinder the growth of the global pharmaceutical CRAM market during the forecast period.
For the detailed list of factors that will drive and challenge the growth of the pharmaceutical contract research and manufacturing (CRAM) market during the 2019-2023, view our report.

Competitive Landscape
The market appears to be moderately concentrated and with the presence of limited vendors. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

Download the full report: https://www.reportbuyer.com/product/5770979/?utm_source=PRN

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: sarah@reportbuyer.com
Tel: +1 (718) 213 4904
Website: www.reportbuyer.com

Cision View original content:http://www.prnewswire.com/news-releases/the-pharmaceutical-contract-research-and-manufacturing-cram-market-will-register-a-cagr-of-more-than-9-by-2023-300837429.html

SOURCE ReportBuyer

Copyright 2019 PR Newswire Association LLC. Back to overview list
to the top ↑